EP3653713A4 - Anti-bril antibody and stabilization method of bril fusion protein using said antibody - Google Patents

Anti-bril antibody and stabilization method of bril fusion protein using said antibody Download PDF

Info

Publication number
EP3653713A4
EP3653713A4 EP18832377.8A EP18832377A EP3653713A4 EP 3653713 A4 EP3653713 A4 EP 3653713A4 EP 18832377 A EP18832377 A EP 18832377A EP 3653713 A4 EP3653713 A4 EP 3653713A4
Authority
EP
European Patent Office
Prior art keywords
antibody
bril
fusion protein
stabilization method
bril fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18832377.8A
Other languages
German (de)
French (fr)
Other versions
EP3653713A1 (en
Inventor
Hikaru Miyagi
Michihiko Suzuki
Junichi Saito
Hidetsugu Asada
So Iwata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co Ltd filed Critical Kyowa Kirin Co Ltd
Publication of EP3653713A1 publication Critical patent/EP3653713A1/en
Publication of EP3653713A4 publication Critical patent/EP3653713A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP18832377.8A 2017-07-13 2018-07-12 Anti-bril antibody and stabilization method of bril fusion protein using said antibody Pending EP3653713A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017137269 2017-07-13
PCT/JP2018/026408 WO2019013308A1 (en) 2017-07-13 2018-07-12 Anti-bril antibody and stabilization method of bril fusion protein using said antibody

Publications (2)

Publication Number Publication Date
EP3653713A1 EP3653713A1 (en) 2020-05-20
EP3653713A4 true EP3653713A4 (en) 2021-03-31

Family

ID=65001382

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18832377.8A Pending EP3653713A4 (en) 2017-07-13 2018-07-12 Anti-bril antibody and stabilization method of bril fusion protein using said antibody

Country Status (5)

Country Link
US (2) US11091545B2 (en)
EP (1) EP3653713A4 (en)
JP (2) JP6577691B2 (en)
CN (1) CN110914430B (en)
WO (1) WO2019013308A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114276460B (en) * 2022-03-04 2022-06-24 水木未来(北京)科技有限公司 Modified GPR75 and use thereof
WO2024143531A1 (en) * 2022-12-28 2024-07-04 国立大学法人東京大学 Sequence extraction system, sequence extraction method, and sequence extraction program
WO2024187408A1 (en) * 2023-03-15 2024-09-19 中国科学技术大学 Universal method for modification and protein structure analysis of target protein

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012148586A1 (en) * 2011-03-15 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Gpcr fusion protein containing an n-terminal autonomously folding stable domain, and crystals of the same
WO2012158555A2 (en) * 2011-05-13 2012-11-22 Receptos, Inc. Novel fusion partners for the purpose of crystallizing g-protein coupled receptors
WO2015148984A2 (en) * 2014-03-27 2015-10-01 Ruiyi Inc. Antibodies that bind human cannabinoid 1 (cb1) receptor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58110600A (en) 1981-12-25 1983-07-01 Kyowa Hakko Kogyo Co Ltd Recombinant plasmid containing human beta-interferon gene
JPS60221091A (en) 1983-12-21 1985-11-05 Kyowa Hakko Kogyo Co Ltd Novel promoter
JP2564268B2 (en) 1985-08-28 1996-12-18 協和醗酵工業株式会社 Fusion antigen polypeptide
ZA872705B (en) 1986-04-22 1987-10-05 Immunex Corporation Human g-csf protein expression
JP2928287B2 (en) 1988-09-29 1999-08-03 協和醗酵工業株式会社 Novel polypeptide
JPH0322979A (en) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd Novel plasminogen-activation factor
AU690474B2 (en) 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
WO1998041861A1 (en) * 1997-03-14 1998-09-24 University Of Guelph Method for determining predisposition to boar taint
JP4896022B2 (en) 2005-04-15 2012-03-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 Method and kit for immunochemical measurement of cytochrome c
JP4835573B2 (en) 2007-10-26 2011-12-14 パナソニック株式会社 Substrate transport apparatus and substrate transport method
CA2765242C (en) 2009-06-11 2019-08-27 Inter-University Research Institute Corporation Research Organization Of Information And Systems Method for producing proteins comprising introducing tol1 or tol2 transposons into suspension cho cells
US10040867B2 (en) * 2014-03-04 2018-08-07 Yale University Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations
JP6677954B2 (en) 2016-02-05 2020-04-08 御木本製薬株式会社 Hyaluronic acid synthase gene expression promoter

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012148586A1 (en) * 2011-03-15 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Gpcr fusion protein containing an n-terminal autonomously folding stable domain, and crystals of the same
WO2012158555A2 (en) * 2011-05-13 2012-11-22 Receptos, Inc. Novel fusion partners for the purpose of crystallizing g-protein coupled receptors
WO2015148984A2 (en) * 2014-03-27 2015-10-01 Ruiyi Inc. Antibodies that bind human cannabinoid 1 (cb1) receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROBERT K. Y. CHENG ET AL: "Structural insight into allosteric modulation of protease-activated receptor 2", NATURE, vol. 545, no. 7652, 4 May 2017 (2017-05-04), London, pages 112 - 115, XP055389810, ISSN: 0028-0836, DOI: 10.1038/nature22309 *
SØREN G F RASMUSSEN ET AL: "Structure of a nanobody-stabilized active state of the .beta.2 adrenoceptor", NATURE, SPRINGER NATURE PUBLISHING AG, LONDON, vol. 469, no. 7329, 13 January 2011 (2011-01-13), pages 175 - 180, XP002677648, ISSN: 1476-4687, [retrieved on 20110112], DOI: 10.1038/NATURE09648 *

Also Published As

Publication number Publication date
CN110914430A (en) 2020-03-24
US20210309738A1 (en) 2021-10-07
WO2019013308A1 (en) 2019-01-17
JPWO2019013308A1 (en) 2019-08-08
JP6577691B2 (en) 2019-09-18
US11773161B2 (en) 2023-10-03
US11091545B2 (en) 2021-08-17
EP3653713A1 (en) 2020-05-20
US20200157211A1 (en) 2020-05-21
JP2019203019A (en) 2019-11-28
CN110914430B (en) 2023-11-21

Similar Documents

Publication Publication Date Title
IL288373A (en) Flt3l-fc fusion proteins and methods of use
EP3820496A4 (en) Fusion constructs and methods of using thereof
EP3402494A4 (en) Chimeric proteins and methods of immunotherapy
EP3820887A4 (en) Pd1-4-1bbl variant fusion protein and methods of use thereof
EP3331608A4 (en) Factor ix fusion proteins and methods of making and using same
EP3515478A4 (en) Antibodies for siglec-15 and methods of use thereof
EP3655006A4 (en) Ultra-long acting insulin-fc fusion proteins and methods of use
EP3481413A4 (en) Fusion protein comprising leptin and methods for producing and using the same
EP3645742A4 (en) Anti-ror1 antibodies and methods of making and using thereof
EP3802812A4 (en) Rna-targeting fusion protein compositions and methods for use
EP3565579A4 (en) A pd1-41bbl fusion protein and methods of use thereof
EP3565828B8 (en) A sirpalpha-4-1bbl fusion protein and methods of use thereof
EP3675906A4 (en) Anti-tm4sf1 antibodies and methods of using same
EP3491025A4 (en) Fcrn antibodies and methods of use thereof
IL281641A (en) Methods and uses of variant cd80 fusion proteins and related constructs
EP3706786A4 (en) Bispecific fusion polypeptides and methods of use thereof
EP3663319A4 (en) Preparation method for novel fusion protein and use of fusion protein for improving protein synthesis
EP3600429A4 (en) Il-37 fusion protein and methods of making and using same
EP3814385A4 (en) Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
EP3431506A4 (en) Multi-functional fusion polypeptide, preparation method thereof, and application of same
EP3980067A4 (en) Antibody-interleukin fusion protein and methods of use
EP3601580A4 (en) Norovirus fusion proteins and vlps comprising norovirus fusion proteins
EP3722305A4 (en) Hm-3 fusion protein and use thereof
EP3604343A4 (en) Fusion protein, preparation method therefor and use thereof
EP3668551A4 (en) Apom-fc fusion proteins and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200110

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210225

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/09 20060101ALI20210219BHEP

Ipc: C12N 15/13 20060101AFI20210219BHEP

Ipc: C07K 14/705 20060101ALI20210219BHEP

Ipc: C07K 19/00 20060101ALI20210219BHEP

Ipc: C07K 16/00 20060101ALI20210219BHEP

Ipc: C07K 16/40 20060101ALI20210219BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230317